article thumbnail

Bharat Biotech and GSK pledge to lower malaria vaccine price under Gavi replenishment initiative

Express Pharma

Bharat Biotech International (BBIL) and GSK plc have announced a joint pledge to Gavi, the Vaccine Alliance, as part of the continued global roll-out of the RTS,S malaria vaccine. The companies confirmed a phased reduction in the vaccine’s price to below USD 5 by 2028.

article thumbnail

Real estate continues to fuel growth of Indian life sciences; provide platform for global ascent in 2025

Express Pharma

Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Hyderabad: Accelerating the future of life sciences

Express Pharma

Consider the balance of the global pharmaceutical and vaccine supply chain. The fact that this single city accounts for roughly one-third of India’s pharmaceutical output and a similar proportion of global vaccine production underscores its role in global health. Hyderabad is becoming a hub in this process.

article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

Research has reported that fear of needles constitutes about 20-50 per cent among children and 20-30 per cent among adults globally; often leading to missed vaccinations and delayed treatments. How does the company collaborate with pharma and vaccine companies to optimise efficacy of medicines with this delivery system?

article thumbnail

Merck agrees to acquire Verona Pharma for $10bn

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters.

article thumbnail

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Dive

But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place. says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m. Last year, Jakafi brought in nearly $2.8 billion in sales.